aTyr Pharma shares are trading lower. The company announced it reached alignment with the FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis.

Benzinga Newsdesk www.benzinga.com Positive 59.5%

Neg 0% Neu 0% Pos 59.5%

Comments

No comments yet. Be the first!